Table 1.

Characteristics of the colorectal cancer cases and matched controls

CasesControls
Number of subjects6075,837
Males (%)384 (63.3)3,712 (63.6)
Age at index date (y), mean (SD)a72.8 (8.7)72.5 (8.5)
Duration of follow-up (y), mean (SD)a4.8 (3.1)4.8 (2.9)
Diabetes duration (y), mean (SD)b2.0 (3.4)2.1 (3.9)
HbA1c (%), median, n (%)7.37.1
 <6.599 (16.3)1,067 (18.3)
 6.5–7.4185 (30.5)1,860 (31.9)
 7.5–8.9144 (23.7)1,224 (21.0)
 ≥964 (10.5)545 (9.3)
 Unknown115 (19.0)1,141 (19.6)
BMI (kg/m2), n (%)
 <18.52 (0.3)30 (0.5)
 18.5–25121 (19.9)1,082 (18.5)
 25–30235 (38.7)2,339 (40.1)
 ≥30232 (38.2)2,278 (39.0)
 Unknown17 (2.8)108 (1.9)
Smoking status, n (%)
 Never235 (38.7)2,243 (38.4)
 Ever356 (58.7)3,447 (59.0)
 Unknown16 (2.6)147 (2.5)
Excessive alcohol use, n (%)74 (12.2)623 (10.7)
Referrals to colonoscopy, n (%)24 (4.0)204 (3.5)
Referrals to sigmoidoscopy, n (%)7 (1.2)75 (1.3)
History of polyps, n (%)18 (3.0)105 (1.8)
Inflammatory bowel disease, n (%)8 (1.3)90 (1.5)
Cholecystectomy, n (%)39 (6.4)317 (5.4)
Ever use of nonsteroidal anti-inflammatory drugs, n (%)358 (58.8)3,424 (58.7)
Ever use of aspirin, n (%)347 (57.2)3,412 (58.5)
Ever use of statins, n (%)357 (58.8)3,643 (62.4)
  • aControls matched to cases on these variables along with year of cohort entry.

  • bDiabetes duration before cohort entry.